- Home
- CALX vs SLNO Comparison
CALX vs SLNO Comparison
Compare CALX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- SLNO
- Stock Information
- Founded
- CALX 1999
- SLNO 1999
- Country
- CALX United States
- SLNO United States
- Employees
- CALX N/A
- SLNO N/A
- Industry
- CALX Telecommunications Equipment
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CALX Consumer Discretionary
- SLNO Health Care
- Exchange
- CALX Nasdaq
- SLNO Nasdaq
- Market Cap
- CALX 2.2B
- SLNO 3.2B
- IPO Year
- CALX 2010
- SLNO 2014
- Fundamental
- Price
- CALX $42.63
- SLNO $76.26
- Analyst Decision
- CALX Strong Buy
- SLNO Strong Buy
- Analyst Count
- CALX 5
- SLNO 9
- Target Price
- CALX $47.40
- SLNO $103.33
- AVG Volume (30 Days)
- CALX 1.2M
- SLNO 958.9K
- Earning Date
- CALX 04-21-2025
- SLNO 05-07-2025
- Dividend Yield
- CALX N/A
- SLNO N/A
- EPS Growth
- CALX N/A
- SLNO N/A
- EPS
- CALX N/A
- SLNO N/A
- Revenue
- CALX $825,450,000.00
- SLNO N/A
- Revenue This Year
- CALX $10.66
- SLNO N/A
- Revenue Next Year
- CALX $9.99
- SLNO N/A
- P/E Ratio
- CALX N/A
- SLNO N/A
- Revenue Growth
- CALX N/A
- SLNO N/A
- 52 Week Low
- CALX $28.61
- SLNO $36.93
- 52 Week High
- CALX $42.50
- SLNO $80.91
- Technical
- Relative Strength Index (RSI)
- CALX 72.84
- SLNO 64.44
- Support Level
- CALX $41.08
- SLNO $72.23
- Resistance Level
- CALX $42.22
- SLNO $76.60
- Average True Range (ATR)
- CALX 1.34
- SLNO 3.04
- MACD
- CALX 0.46
- SLNO -0.41
- Stochastic Oscillator
- CALX 97.91
- SLNO 63.12
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.